CXCR2 and Alzheimer disease: Furthermore, results of neutralizing experiments showed that the anti-CXCR2 antibody effectively blocked CXCL1-overexpressing THP-1 cells (Figure 4E) and AD patients’ monocytes (Figure 4F) migration through the in vitro BBB model, when Aβ was added to the lower chamber.